OTCMUCBJY
Market cap36bUSD
Dec 20, Last price
97.35USD
1D
1.65%
1Q
7.00%
Jan 2017
200.19%
Name
Ucb SA
Chart & Performance
Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 5,252,000 -4.80% | 5,517,000 -4.50% | 5,777,000 8.04% | |||||||
Cost of revenue | 5,161,000 | 5,247,000 | 4,795,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 91,000 | 270,000 | 982,000 | |||||||
NOPBT Margin | 1.73% | 4.89% | 17.00% | |||||||
Operating Taxes | 98,000 | 91,000 | 170,000 | |||||||
Tax Rate | 107.69% | 33.70% | 17.31% | |||||||
NOPAT | (7,000) | 179,000 | 812,000 | |||||||
Net income | 343,000 -17.94% | 418,000 -60.49% | 1,058,000 44.54% | |||||||
Dividends | (252,000) | (247,000) | (240,000) | |||||||
Dividend yield | 1.64% | 1.72% | 1.23% | |||||||
Proceeds from repurchase of equity | (40,000) | (405,000) | 779,000 | |||||||
BB yield | 0.26% | 2.83% | -4.00% | |||||||
Debt | ||||||||||
Debt current | 85,000 | 262,000 | 55,000 | |||||||
Long-term debt | 3,157,000 | 2,638,000 | 2,068,000 | |||||||
Deferred revenue | 100,000 | 97,000 | ||||||||
Other long-term liabilities | 666,000 | 677,000 | 741,000 | |||||||
Net debt | 2,150,000 | 1,653,000 | 565,000 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 761,000 | 1,045,000 | 1,490,000 | |||||||
CAPEX | (238,000) | (371,000) | (493,000) | |||||||
Cash from investing activities | (440,000) | (1,580,000) | (487,000) | |||||||
Cash from financing activities | (308,000) | 144,000 | (1,056,000) | |||||||
FCF | (225,000) | 20,000 | 572,000 | |||||||
Balance | ||||||||||
Cash | 923,000 | 1,069,000 | 1,373,000 | |||||||
Long term investments | 169,000 | 178,000 | 185,000 | |||||||
Excess cash | 829,400 | 971,150 | 1,269,150 | |||||||
Stockholders' equity | 7,298,000 | 7,397,000 | 6,751,000 | |||||||
Invested Capital | 11,892,600 | 11,619,850 | 9,949,850 | |||||||
ROIC | 1.66% | 8.37% | ||||||||
ROCE | 0.70% | 2.08% | 8.61% | |||||||
EV | ||||||||||
Common stock shares outstanding | 195,190 | 194,834 | 194,177 | |||||||
Price | 78.90 7.26% | 73.56 -26.70% | 100.35 18.79% | |||||||
Market cap | 15,400,491 7.46% | 14,331,989 -26.45% | 19,485,662 18.74% | |||||||
EV | 17,550,491 | 15,984,989 | 20,050,662 | |||||||
EBITDA | 782,000 | 855,000 | 1,305,000 | |||||||
EV/EBITDA | 22.44 | 18.70 | 15.36 | |||||||
Interest | 144,000 | 71,000 | 45,000 | |||||||
Interest/NOPBT | 158.24% | 26.30% | 4.58% |